PAYVANDI, FLORA
PAYVANDI, FLORA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Diverse career paths within thrombosis and hemostasis: perspectives from the ISTH early career committee
2026 J.S. Gauer, N. Potere, T. Chiasakul, S.D. Manevski, S. Kohli, F. Peyvandi, P. Armstrong, T. Chiasakul, S.D. Manevski, A. Iding, S. Kohli, N. Potere, J.S. Gauer, Z. Sayar, S. Sewaralthahab, R. Zon, L. Poole, R. Eslick
Orthopaedic Surgery Outcomes in Patients With Haemophilia A or B Treated With Extended Half‐Life Recombinant Factor VIII and IX Fc Fusion Proteins: A Multicentre Prospective Study
2025 L.P. Solimeno, R. Gualtierotti, E. Guido, J. Acquati Lozej, E. Cristini, A. Ciavarella, S. Arcudi, C. Carulli, L. Pieri, S.M. Siboni, F. Peyvandi
Impact of blood centrifugation on the parameters of thrombin generation assay revisited to look for possible revision of the current guidance
2025 E. Scalambrino, M. Clerici, F. Peyvandi, A. Tripodi
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates
2025 H. Chand, S. Hassan, A. Cairo, R. Palla, F. Peyvandi, F. Peyvandi, P.M. Mannucci, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M.E. Mancuso, A.C. Sandoval Gonzalez, J.N. Mahlangu, S. Bonanad Boix, M. Cerqueira, N.P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N.L. Kobrinsky, S. Majumdar, R.P. Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakli, M.J. Manco-Johnson, M. Martinez, E. Marzouka, M.G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B.M. Wicklund, B. Zulfikar, F.R. Rosendaal
Design organization and clinical processes around patient characteristics: Evidence from a multiple case study of Hemophilia
2025 S. Villa, R. De Cristofaro, G. Di Minno, S. Laratro, F. Peyvandi, L. Pippo, S. Villa, A.G. De Belvis
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A
2025 A. Gringeri, P.M. Mannucci, M. Gringeri, G. Castaman, F. Peyvandi
Therapeutic plasma exchange-related complications in patients with immune-mediated thrombotic thrombocytopenic purpura: Complications of therapeutic plasma-exchange
2025 P. Agosti, I. Mancini, A. Artoni, C. Cardone, P. De Leo, C. Bichard, A. Truma, B. Ferrari, J.A. Giannotta, N.N. Fantini, M.C. Mocellin, D. Prati, F. Peyvandi
Operationalising a Haemophilia Gene Editing Lexicon for Practical Use
2025 W. Mckeown, C. Hermans, C. Unzu, M.A. Kay, F. Peyvandi, P. Smith, W. Miesbach, G.F. Pierce, K. Khair, L.A. Valentino, S.W. Pipe, M. Pillai, M. Jones, V. Delwart, A. Sindhurakar, D.E. Gutstein, C.M. Kessler
Global prevalence of platelet-type von Willebrand disease
2025 O. Seidizadeh, A. Cairo, M. Othman, F. Peyvandi
Adeno-associated virus-based gene therapy for hemophilia–addressing the gaps
2025 W. Miesbach, P. Batty, P. Chowdary, S. Fong, R. Kaczmarek, F.W.G. Leebeek, B. Long, J. Mahlangu, M. Makris, G.F. Pierce, S.W. Pipe, A. Srivastava, J. Voorberg, F. Peyvandi
Gene therapy in hemophilia: the dawn of a new era
2025 R. Gualtierotti, A. Giachi, N. Bitto, V. La Mura, F. Peyvandi
Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry
2025 K. Fischer, R. Lassila, F. Peyvandi, A. Gatt, S.C. Gouw, R. Hollingsworth, T. Lambert, R. Kaczmarek, D. Carbonero, M. Makris
Challenges and considerations of genetic testing in von Willebrand disease
2025 O. Seidizadeh, L. Baronciani, F. Peyvandi
Inhibitor development in nonsevere hemophilia: data from the European Haemophilia Safety Surveillance (EUHASS) registry
2025 K. Fischer, R. Lassila, F. Peyvandi, A. Gatt, S.C. Gouw, R. Hollingsworth, T. Lambert, R. Kaczmarek, D.C. Alvarez, M. Makris
Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor–platelet interaction
2025 P. Colpani, L. Baronciani, I. Mancini, C. Novembrino, A. Lecchi, G. Cozzi, P. De Leo, M.B. Anzoletti, S. La Marca, M. Boscarino, M.T. Pagliari, A. Artoni, F. Peyvandi
Clarifying the role of p.Gln723Lys in hTTP prevalence
2025 O. Seidizadeh, A. Cairo, I. Mancini, J.N. George, F. Peyvandi
Involvement of the contact pathway in COVID-19 coagulopathy
2025 M. Capecchi, C. Novembrino, M. Abbattista, M. Boscolo-Anzoletti, E. Galbiati, S. Griffini, E. Grovetti, L. Valenti, F. Blasi, G. Grasselli, R. Gualtierotti, M. Cugno, F. Peyvandi
Thrombin Generation Assays: What are the Current Clinical Applications?
2025 A. Tripodi, M. Clerici, E. Scalambrino, F. Peyvandi
Qualification Criteria of Gene Therapy for Haemophilia-Opinion of the EAHAD Gene Therapy Working Group
2025 W. Miesbach, A. Boban, P. Chowdary, M. Coppens, V. Jimenez-Yuste, R. Klamroth, G. Mulders, M. Crato, F. Peyvandi
Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study.
2025 J. Oldenburg, C. Hay, F. Peyvandi, A. Tagliaferri, P.A. Holme, M.T. Álvarez‐román, C. Biron‐andréani, H. Malmström, L. Bystrická, S. Lethagen, N. Null